Rash & Diarrhea Prophylaxis With Capivasertib

This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen.

NCT Number	NCT07426822
Lead Sponsor	Maryam Lustberg Collaborators: AstraZeneca
Conditions	Metastatic HR+/HER2- Breast Cancer
Enrollment	108 participants
Start Date	2026-08-15
Primary Completion	2027-04 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-29